Newer antifungal agents for invasive fungal infections in patients with haematological malignancy.
Since 2001 five new systemically administered antifungal agents have been approved for clinical use. This represents a major advance for antifungal therapy in haematological malignancy patients undergoing chemotherapy or haematopoietic stem cell transplant (HSCT). The echinocandins are a new class of antifungals with a novel mode of action. Capsofungin has already established itself as a valuable therapy for candidaemia and salvage therapy of invasive aspergillosis. Although both anidulafungin and micafungin are approved for treatment of candidiasis, their role in invasive aspergillosis requires more clinical trial evaluation. Of the two newer triazoles, voriconazole has been recommended in international guidelines as primary therapy for acute invasive aspergillosis. Posaconazole has a broad spectrum of activity in vitro and a potentially key role in antifungal prophylaxis in high-risk HSCT recipients and during prolonged neutropenia. Although some of these drugs have important interactions with other medications, and potential toxicities, they are safer to use and more efficacious than amphotericin B deoxycholate. Their arrival gives more choices to treat rarer mycoses and will facilitate clinical trial assessment of combination therapy of aspergillosis where single agent therapy gives less than 50% success rates.
Rogers
Thomas R
TR
Department of Clinical Microbiology, Trinity College Dublin, St James's Hospital Campus, Dublin, Ireland. rogerstr@tcd.ie
Frost
Susanna
S
D000935:Antifungal Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D054714:Echinocandins / Q000627:therapeutic use; D005544:Forecasting; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000382:microbiology*; D006801:Humans; D009181:Mycoses / Q000188:drug therapy*; D009894:Opportunistic Infections / Q000188:drug therapy*
D000935:Antifungal Agents; D054714:Echinocandins